

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 January 2023 (19.01.2023)



(10) International Publication Number
WO 2023/288338 A2

- (51) **International Patent Classification:**
C12N 15/85 (2006.01) A61K 48/00 (2006.01)
- (21) **International Application Number:**
PCT/US2022/073862
- (22) **International Filing Date:**
18 July 2022 (18.07.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/222,954 16 July 2021 (16.07.2021) US
63/282,961 24 November 2021 (24.11.2021) US
- (71) **Applicant: SANA BIOTECHNOLOGY, INC.** [US/US];
188 E. Blaine St, Suite 400, Seattle, Washington 98102 (US).
- (72) **Inventors: MATIAS, Albert Rufo;** 188 E. Blaine St, Suite 400, Seattle, Washington 98102 (US). **DOWDLE, William;** 188 E. Blaine St, Suite 400, Seattle, Washington 98102 (US). **THAM, Eleonore;** 188 E. Blaine St, Suite 400, Seattle, Washington 98102 (US). **ELMAN, Jessica S.;** 188 E. Blaine St, Suite 400, Seattle, Washington 98102 (US). **JOHNSON, Adam;** 188 E. Blaine St, Suite 400, Seattle, Washington 98102 (US).
- (74) **Agent: XING, Mengke;** PERKINS COIE LLP, P.O. Box 1247, Seattle, Washington 98111-1247 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) **Title:** POLYCISTRONIC VECTORS FOR CELL-BASED THERAPIES




FIG. 1A

(57) **Abstract:** Provided are polycistronic vectors for co-expression of one or more tolerogenic factors, one or more CARs, and optionally one or more safety switches, as well as compositions comprising the same, cells comprising the same and methods of generating those cells, and methods of using the disclosed vectors, compositions, and cells to treat diseases such as cancer, diabetes, and neurological diseases.

WO 2023/288338 A2